TE 8035
Alternative Names: TE-8035Latest Information Update: 10 Feb 2023
Price :
$50 *
At a glance
- Originator Immunwork
- Class Antihyperglycaemics; Drug conjugates; Fatty acids; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 05 Jan 2023 TE 8035 is available for licensing as of 05 Jan 2023. https://www.immunwork.com/eforms.php?lang=en&tb=1
- 05 Jan 2023 Preclinical trials in Diabetes mellitus in Taiwan (SC) before January 2023 (Immunwork pipeline, January 2023)
- 05 Jan 2023 Pharmacodynamics data from preclinical studies in Diabetes mellitus released by Immunwork (Immunwork pipeline, January 2023)